Serum HER2 level measured by dot blot: a valid and inexpensive assay for monitoring breast cancer progression.

Human epidermal growth factor receptor 2 (HER2) is one of the most important prognostic and predictive factors for breast cancer patients. Recently, serum HER2 ECD level of patients detected by enzyme-linked immunoabsorbent assay (ELISA) has been shown to predict tumor HER2 status and reveal its ass...

Full description

Bibliographic Details
Main Authors: Li-Duan Tan, Yuan-Yuan Xu, Yue Yu, Xiao-Qing Li, Ying Chen, Yu-Mei Feng
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3076436?pdf=render
id doaj-8822b6c3a8b54384b0730221b399b3be
record_format Article
spelling doaj-8822b6c3a8b54384b0730221b399b3be2020-11-25T00:04:42ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0164e1876410.1371/journal.pone.0018764Serum HER2 level measured by dot blot: a valid and inexpensive assay for monitoring breast cancer progression.Li-Duan TanYuan-Yuan XuYue YuXiao-Qing LiYing ChenYu-Mei FengHuman epidermal growth factor receptor 2 (HER2) is one of the most important prognostic and predictive factors for breast cancer patients. Recently, serum HER2 ECD level of patients detected by enzyme-linked immunoabsorbent assay (ELISA) has been shown to predict tumor HER2 status and reveal its association with tumor progression, recurrence and poor prognosis. In this study, we established a new method, dot blot assay, to measure the serum HER2 level in breast cancer patients and further to evaluate the clinical value for monitoring breast cancer progression. We found that the serum HER2 level measured by dot blot assay was significantly correlated with tissue HER2 status in breast cancer patients (P = 0.001), and also significantly correlated with HER2 level measured by ELISA (P = 1.06×10(-11)). Compared with ELISA method, the specificity and sensitivity of dot blot assay were 95.3% and 65.0%, respectively. The serum HER2 levels of patients with grade III or ER-negative were higher than those with grade I-II (P = 0.004) and ER-positive (P = 0.033), respectively. Therefore, the novel dot blot method to detect serum HER2 level is a valid and inexpensive assay with potential application in monitoring breast cancer progression in clinical situations.http://europepmc.org/articles/PMC3076436?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Li-Duan Tan
Yuan-Yuan Xu
Yue Yu
Xiao-Qing Li
Ying Chen
Yu-Mei Feng
spellingShingle Li-Duan Tan
Yuan-Yuan Xu
Yue Yu
Xiao-Qing Li
Ying Chen
Yu-Mei Feng
Serum HER2 level measured by dot blot: a valid and inexpensive assay for monitoring breast cancer progression.
PLoS ONE
author_facet Li-Duan Tan
Yuan-Yuan Xu
Yue Yu
Xiao-Qing Li
Ying Chen
Yu-Mei Feng
author_sort Li-Duan Tan
title Serum HER2 level measured by dot blot: a valid and inexpensive assay for monitoring breast cancer progression.
title_short Serum HER2 level measured by dot blot: a valid and inexpensive assay for monitoring breast cancer progression.
title_full Serum HER2 level measured by dot blot: a valid and inexpensive assay for monitoring breast cancer progression.
title_fullStr Serum HER2 level measured by dot blot: a valid and inexpensive assay for monitoring breast cancer progression.
title_full_unstemmed Serum HER2 level measured by dot blot: a valid and inexpensive assay for monitoring breast cancer progression.
title_sort serum her2 level measured by dot blot: a valid and inexpensive assay for monitoring breast cancer progression.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2011-01-01
description Human epidermal growth factor receptor 2 (HER2) is one of the most important prognostic and predictive factors for breast cancer patients. Recently, serum HER2 ECD level of patients detected by enzyme-linked immunoabsorbent assay (ELISA) has been shown to predict tumor HER2 status and reveal its association with tumor progression, recurrence and poor prognosis. In this study, we established a new method, dot blot assay, to measure the serum HER2 level in breast cancer patients and further to evaluate the clinical value for monitoring breast cancer progression. We found that the serum HER2 level measured by dot blot assay was significantly correlated with tissue HER2 status in breast cancer patients (P = 0.001), and also significantly correlated with HER2 level measured by ELISA (P = 1.06×10(-11)). Compared with ELISA method, the specificity and sensitivity of dot blot assay were 95.3% and 65.0%, respectively. The serum HER2 levels of patients with grade III or ER-negative were higher than those with grade I-II (P = 0.004) and ER-positive (P = 0.033), respectively. Therefore, the novel dot blot method to detect serum HER2 level is a valid and inexpensive assay with potential application in monitoring breast cancer progression in clinical situations.
url http://europepmc.org/articles/PMC3076436?pdf=render
work_keys_str_mv AT liduantan serumher2levelmeasuredbydotblotavalidandinexpensiveassayformonitoringbreastcancerprogression
AT yuanyuanxu serumher2levelmeasuredbydotblotavalidandinexpensiveassayformonitoringbreastcancerprogression
AT yueyu serumher2levelmeasuredbydotblotavalidandinexpensiveassayformonitoringbreastcancerprogression
AT xiaoqingli serumher2levelmeasuredbydotblotavalidandinexpensiveassayformonitoringbreastcancerprogression
AT yingchen serumher2levelmeasuredbydotblotavalidandinexpensiveassayformonitoringbreastcancerprogression
AT yumeifeng serumher2levelmeasuredbydotblotavalidandinexpensiveassayformonitoringbreastcancerprogression
_version_ 1725428488633057280